514 related articles for article (PubMed ID: 23602910)
1. PGC-1α, mitochondrial dysfunction, and Huntington's disease.
Johri A; Chandra A; Flint Beal M
Free Radic Biol Med; 2013 Sep; 62():37-46. PubMed ID: 23602910
[TBL] [Abstract][Full Text] [Related]
2. Meldonium improves Huntington's disease mitochondrial dysfunction by restoring peroxisome proliferator-activated receptor γ coactivator 1α expression.
Di Cristo F; Finicelli M; Digilio FA; Paladino S; Valentino A; Scialò F; D'Apolito M; Saturnino C; Galderisi U; Giordano A; Melone MAB; Peluso G
J Cell Physiol; 2019 Jun; 234(6):9233-9246. PubMed ID: 30362565
[TBL] [Abstract][Full Text] [Related]
3. PGC-1α at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond.
Tsunemi T; La Spada AR
Prog Neurobiol; 2012 May; 97(2):142-51. PubMed ID: 22100502
[TBL] [Abstract][Full Text] [Related]
4. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.
Chaturvedi RK; Calingasan NY; Yang L; Hennessey T; Johri A; Beal MF
Hum Mol Genet; 2010 Aug; 19(16):3190-205. PubMed ID: 20529956
[TBL] [Abstract][Full Text] [Related]
5. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.
Weydt P; Pineda VV; Torrence AE; Libby RT; Satterfield TF; Lazarowski ER; Gilbert ML; Morton GJ; Bammler TK; Strand AD; Cui L; Beyer RP; Easley CN; Smith AC; Krainc D; Luquet S; Sweet IR; Schwartz MW; La Spada AR
Cell Metab; 2006 Nov; 4(5):349-62. PubMed ID: 17055784
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.
Cui L; Jeong H; Borovecki F; Parkhurst CN; Tanese N; Krainc D
Cell; 2006 Oct; 127(1):59-69. PubMed ID: 17018277
[TBL] [Abstract][Full Text] [Related]
7. PGC-1alpha, a new therapeutic target in Huntington's disease?
McGill JK; Beal MF
Cell; 2006 Nov; 127(3):465-8. PubMed ID: 17081970
[TBL] [Abstract][Full Text] [Related]
8. Activating mitochondrial regulator PGC-1α expression by astrocytic NGF is a therapeutic strategy for Huntington's disease.
Chen LW; Horng LY; Wu CL; Sung HC; Wu RT
Neuropharmacology; 2012 Sep; 63(4):719-32. PubMed ID: 22633948
[TBL] [Abstract][Full Text] [Related]
9. PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.
Tsunemi T; Ashe TD; Morrison BE; Soriano KR; Au J; Roque RA; Lazarowski ER; Damian VA; Masliah E; La Spada AR
Sci Transl Med; 2012 Jul; 4(142):142ra97. PubMed ID: 22786682
[TBL] [Abstract][Full Text] [Related]
10. Impaired PGC-1alpha function in muscle in Huntington's disease.
Chaturvedi RK; Adhihetty P; Shukla S; Hennessy T; Calingasan N; Yang L; Starkov A; Kiaei M; Cannella M; Sassone J; Ciammola A; Squitieri F; Beal MF
Hum Mol Genet; 2009 Aug; 18(16):3048-65. PubMed ID: 19460884
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease.
Johri A; Calingasan NY; Hennessey TM; Sharma A; Yang L; Wille E; Chandra A; Beal MF
Hum Mol Genet; 2012 Mar; 21(5):1124-37. PubMed ID: 22095692
[TBL] [Abstract][Full Text] [Related]
12. Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis.
Kong X; Wang R; Xue Y; Liu X; Zhang H; Chen Y; Fang F; Chang Y
PLoS One; 2010 Jul; 5(7):e11707. PubMed ID: 20661474
[TBL] [Abstract][Full Text] [Related]
13. The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway.
Yang X; Liu Q; Li Y; Tang Q; Wu T; Chen L; Pu S; Zhao Y; Zhang G; Huang C; Zhang J; Zhang Z; Huang Y; Zou M; Shi X; Jiang W; Wang R; He J
Adipocyte; 2020 Dec; 9(1):484-494. PubMed ID: 32835596
[TBL] [Abstract][Full Text] [Related]
14. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.
Chaturvedi RK; Hennessey T; Johri A; Tiwari SK; Mishra D; Agarwal S; Kim YS; Beal MF
Hum Mol Genet; 2012 Aug; 21(15):3474-88. PubMed ID: 22589249
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor γ, coactivator 1α deletion induces angiotensin II-associated vascular dysfunction by increasing mitochondrial oxidative stress and vascular inflammation.
Kröller-Schön S; Jansen T; Schüler A; Oelze M; Wenzel P; Hausding M; Kerahrodi JG; Beisele M; Lackner KJ; Daiber A; Münzel T; Schulz E
Arterioscler Thromb Vasc Biol; 2013 Aug; 33(8):1928-35. PubMed ID: 23788763
[TBL] [Abstract][Full Text] [Related]
16. The neurogenic basic helix-loop-helix transcription factor NeuroD6 confers tolerance to oxidative stress by triggering an antioxidant response and sustaining the mitochondrial biomass.
Uittenbogaard M; Baxter KK; Chiaramello A
ASN Neuro; 2010 May; 2(2):e00034. PubMed ID: 20517466
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
[TBL] [Abstract][Full Text] [Related]
18. Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis.
Ayala-Peña S
Free Radic Biol Med; 2013 Sep; 62():102-110. PubMed ID: 23602907
[TBL] [Abstract][Full Text] [Related]
19. CTRP3 promotes energy production by inducing mitochondrial ROS and up-expression of PGC-1α in vascular smooth muscle cells.
Feng H; Wang JY; Zheng M; Zhang CL; An YM; Li L; Wu LL
Exp Cell Res; 2016 Feb; 341(2):177-86. PubMed ID: 26844631
[TBL] [Abstract][Full Text] [Related]
20. PGC-1α buffers ROS-mediated removal of mitochondria during myogenesis.
Baldelli S; Aquilano K; Ciriolo MR
Cell Death Dis; 2014 Nov; 5(11):e1515. PubMed ID: 25375380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
